India's intellectual-property police nixed a key patent on Gilead Sciences' hepatitis C drug Sovaldi, opening the door for cheap generic copies from domestic drugmakers such as Natco Pharma. It's the latest blow to a multinational drugmaker's ambitions in India, which remains one of the fastest-growing drug markets in the world.
China's FDA has awarded marketing approval of the world's first Sabin strain inactivated polio vaccine, marking a milestone as well for the Institute of Medical Biology of the Academy of Medical Sciences.
GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.
In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution.
Companies in Egypt have been advertising Indian-made versions of Gilead Sciences' hepatitis C cure Sovaldi for sale. The problem is, none of the 7 drugmakers that were granted the right to produce the drug, 6 of them Indian companies, have gotten past development with the product. That suggests that whatever is being sold in Egypt is not really generic Sovaldi.
As med tech companies set their sails toward China, a new trade agreement between the U.S. and Chinese governments looks to ease restrictions for imports, paving the way for greater expansion by U.S. devicemakers.
U.S. and Chinese trade officials announced on Thursday that China will streamline drug approvals and promised equal treatment of U.S. and Chinese companies in pricing probes.
China's Neusoft will receive $610 million from a variety of investors including Goldman Sachs to fund its medical imaging and healthcare IT ambitions.
Mounting political tensions between Russia and the West may have recently scared Germany's Fresenius out of a partnership in the country. But they won't spook Abbott Laboratories out of its VeroPharm buy, it announced Friday.
Amid escalating tension between Big Pharma and India's National Pharmaceutical Pricing Authority over price caps on "essential drugs," the NPPA has extended its pricing policies to cover 52 additional meds, including commonly used painkillers and antibiotics and drugs for cancer and skin disease treatment.